Jiasheng Bian

机构：Shandong Tumor Hospital, Zhengzhou Railway Vocational & Technical College, Shandong First Medical University

发表论文 24 篇 · 总被引 248 次 · h-index 8

代表论文

• Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer (2025 · New England Journal of Medicine · 被引 76)
• LncRNA RCAT1 promotes tumor progression and metastasis via miR-214-5p/E2F2 axis in renal cell carcinoma (2021 · Cell Death and Disease · 被引 51)
• Comparison of two detection systems for circulating tumor cells among patients with renal cell carcinoma (2018 · International Urology and Nephrology · 被引 25)
• CACA guidelines for holistic integrative management of prostate cancer (2024 · Holistic Integrative Oncology · 被引 22)
• Neoadjuvant treatment with disitamab vedotin plus perioperative toripalimab in patients with muscle-invasive bladder cancer (MIBC) with HER2 expression: Updated efficacy and safety results from the phase II RC48-C017 trial. (2025 · Journal of Clinical Oncology · 被引 18)
• Neoadjuvant therapy combined with a BMP regimen for treating penile cancer patients with lymph node metastasis: a retrospective study in China (2014 · Journal of Cancer Research and Clinical Oncology · 被引 15)